We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BD (BDX) Up on Efforts to Tackle Blood Culture Vial Shortage
Read MoreHide Full Article
Shares of Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, have gained 0.9% since Jul 10, after the company announced reduced availability of blood culture vials due to issues with its supplier. The rise could be likely due to immediate measures taken by the company to mitigate this supply disruption, including leveraging its manufacturing expertise and collaborating with the FDA.
The FDA issued a letter last week to healthcare providers highlighting the supply shortage, underscoring the critical role of blood culture testing in diagnosing and treating infections. The shortage will affect the ability of healthcare providers to efficiently diagnose infections, prompting BD to take immediate actions to ensure continuity of patient care and minimize any potential impact.
More on the News
BD is manually allocating BD BACTEC blood culture vials to mitigate the impact on patient care due to a supply shortage. The company is providing its supplier with its manufacturing expertise, using air shipments and modifying manufacturing schedules for rapid production to address any shortage. The company is also collaborating with the FDA to review all potential options to mitigate delays in supply. It has also planned to restart production at its former supplier of glass vials to help fill the intermittent gap in supply.
The company has advised customers to prioritize vial use based on clinical needs, following guidelines from the Infectious Disease Society of America and the World Health Organization. While BD does not anticipate a significant financial impact from this issue, it is fully focused on restoring the supply of blood culture vials to normal levels.
A Recent Development
Earlier this month, BD introduced the BD Rhapsody Single Cell ATAC-Seq Assay, a groundbreaking tool for single-cell analysis. This new technology allows scientists to examine the epigenome of individual cells, providing insights into the chemical marks on DNA that influence disease mechanisms. By adding an epigenomic layer to their analyses, researchers can better understand how environmental factors affect DNA and cell function, advancing the study of diseases like cancer.
Price Performance
Shares of BD have declined 7.3% so far this year against the industry's 3.7% rise.
The S&P 500 has witnessed an 18.2% rise in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, BD carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the broader medical space are Quest Diagnostics ((DGX - Free Report) , Universal Health Services (UHS - Free Report) and Dexcom (DXCM - Free Report) .
DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.67%. Quest Diagnostics shares have gained 3.2% compared with the industry’s 10.9% rise so far this year.
Universal Health Services, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 15.20%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 8.12%.
Universal Health Services has gained 17.5% compared with the industry's 10.2% rise so far this year.
DexCom, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 22.90%. DXCM’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 34.10%.
DexCom’s shares have declined 17.8% compared with the industry's 1.3% decrease so far this year
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BD (BDX) Up on Efforts to Tackle Blood Culture Vial Shortage
Shares of Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, have gained 0.9% since Jul 10, after the company announced reduced availability of blood culture vials due to issues with its supplier. The rise could be likely due to immediate measures taken by the company to mitigate this supply disruption, including leveraging its manufacturing expertise and collaborating with the FDA.
The FDA issued a letter last week to healthcare providers highlighting the supply shortage, underscoring the critical role of blood culture testing in diagnosing and treating infections. The shortage will affect the ability of healthcare providers to efficiently diagnose infections, prompting BD to take immediate actions to ensure continuity of patient care and minimize any potential impact.
More on the News
BD is manually allocating BD BACTEC blood culture vials to mitigate the impact on patient care due to a supply shortage. The company is providing its supplier with its manufacturing expertise, using air shipments and modifying manufacturing schedules for rapid production to address any shortage. The company is also collaborating with the FDA to review all potential options to mitigate delays in supply. It has also planned to restart production at its former supplier of glass vials to help fill the intermittent gap in supply.
The company has advised customers to prioritize vial use based on clinical needs, following guidelines from the Infectious Disease Society of America and the World Health Organization. While BD does not anticipate a significant financial impact from this issue, it is fully focused on restoring the supply of blood culture vials to normal levels.
A Recent Development
Earlier this month, BD introduced the BD Rhapsody Single Cell ATAC-Seq Assay, a groundbreaking tool for single-cell analysis. This new technology allows scientists to examine the epigenome of individual cells, providing insights into the chemical marks on DNA that influence disease mechanisms. By adding an epigenomic layer to their analyses, researchers can better understand how environmental factors affect DNA and cell function, advancing the study of diseases like cancer.
Price Performance
Shares of BD have declined 7.3% so far this year against the industry's 3.7% rise.
The S&P 500 has witnessed an 18.2% rise in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, BD carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the broader medical space are Quest Diagnostics ((DGX - Free Report) , Universal Health Services (UHS - Free Report) and Dexcom (DXCM - Free Report) .
Quest Diagnostics, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 5.20%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.67%. Quest Diagnostics shares have gained 3.2% compared with the industry’s 10.9% rise so far this year.
Universal Health Services, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 15.20%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 8.12%.
Universal Health Services has gained 17.5% compared with the industry's 10.2% rise so far this year.
DexCom, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 22.90%. DXCM’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 34.10%.
DexCom’s shares have declined 17.8% compared with the industry's 1.3% decrease so far this year